The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Fabry Disease Therapeutic Market Research Report 2025
Synopsis
The global Fabry Disease Therapeutic market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Fabry Disease Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fabry Disease Therapeutic.
Report Scope
The Fabry Disease Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Fabry Disease Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fabry Disease Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amicus therapeutics
Takeda
Genzyme-Sanofi
Protalix
Sanofi-Aventis LLC
Novartis Pharmaceuticals
Pfizer
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Amgen Inc.
Teva pharmaceutical Industries Ltd.
Merc & Co.
AbbVie Inc.
Takeda Pharmaceutical Co. Ltd.
Green Cross Corp.
Segment by Type
Enzyme Replacement Therapy
Alternative therapies
Segment by Application
Hospitals
Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fabry Disease Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Fabry Disease Therapeutic market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Fabry Disease Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fabry Disease Therapeutic.
Report Scope
The Fabry Disease Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Fabry Disease Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Fabry Disease Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amicus therapeutics
Takeda
Genzyme-Sanofi
Protalix
Sanofi-Aventis LLC
Novartis Pharmaceuticals
Pfizer
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Amgen Inc.
Teva pharmaceutical Industries Ltd.
Merc & Co.
AbbVie Inc.
Takeda Pharmaceutical Co. Ltd.
Green Cross Corp.
Segment by Type
Enzyme Replacement Therapy
Alternative therapies
Segment by Application
Hospitals
Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fabry Disease Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Fabry Disease Therapeutic Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Enzyme Replacement Therapy
1.2.3 Alternative therapies
1.3 Market by Application
1.3.1 Global Fabry Disease Therapeutic Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Fabry Disease Therapeutic Market Perspective (2019-2030)
2.2 Fabry Disease Therapeutic Growth Trends by Region
2.2.1 Global Fabry Disease Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Fabry Disease Therapeutic Historic Market Size by Region (2019-2024)
2.2.3 Fabry Disease Therapeutic Forecasted Market Size by Region (2025-2030)
2.3 Fabry Disease Therapeutic Market Dynamics
2.3.1 Fabry Disease Therapeutic Industry Trends
2.3.2 Fabry Disease Therapeutic Market Drivers
2.3.3 Fabry Disease Therapeutic Market Challenges
2.3.4 Fabry Disease Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Fabry Disease Therapeutic Players by Revenue
3.1.1 Global Top Fabry Disease Therapeutic Players by Revenue (2019-2024)
3.1.2 Global Fabry Disease Therapeutic Revenue Market Share by Players (2019-2024)
3.2 Global Fabry Disease Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Fabry Disease Therapeutic Revenue
3.4 Global Fabry Disease Therapeutic Market Concentration Ratio
3.4.1 Global Fabry Disease Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Fabry Disease Therapeutic Revenue in 2023
3.5 Fabry Disease Therapeutic Key Players Head office and Area Served
3.6 Key Players Fabry Disease Therapeutic Product Solution and Service
3.7 Date of Enter into Fabry Disease Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Fabry Disease Therapeutic Breakdown Data by Type
4.1 Global Fabry Disease Therapeutic Historic Market Size by Type (2019-2024)
4.2 Global Fabry Disease Therapeutic Forecasted Market Size by Type (2025-2030)
5 Fabry Disease Therapeutic Breakdown Data by Application
5.1 Global Fabry Disease Therapeutic Historic Market Size by Application (2019-2024)
5.2 Global Fabry Disease Therapeutic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Fabry Disease Therapeutic Market Size (2019-2030)
6.2 North America Fabry Disease Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Fabry Disease Therapeutic Market Size by Country (2019-2024)
6.4 North America Fabry Disease Therapeutic Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Fabry Disease Therapeutic Market Size (2019-2030)
7.2 Europe Fabry Disease Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Fabry Disease Therapeutic Market Size by Country (2019-2024)
7.4 Europe Fabry Disease Therapeutic Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Fabry Disease Therapeutic Market Size (2019-2030)
8.2 Asia-Pacific Fabry Disease Therapeutic Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Fabry Disease Therapeutic Market Size by Region (2019-2024)
8.4 Asia-Pacific Fabry Disease Therapeutic Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Fabry Disease Therapeutic Market Size (2019-2030)
9.2 Latin America Fabry Disease Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Fabry Disease Therapeutic Market Size by Country (2019-2024)
9.4 Latin America Fabry Disease Therapeutic Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Fabry Disease Therapeutic Market Size (2019-2030)
10.2 Middle East & Africa Fabry Disease Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Fabry Disease Therapeutic Market Size by Country (2019-2024)
10.4 Middle East & Africa Fabry Disease Therapeutic Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amicus therapeutics
11.1.1 Amicus therapeutics Company Detail
11.1.2 Amicus therapeutics Business Overview
11.1.3 Amicus therapeutics Fabry Disease Therapeutic Introduction
11.1.4 Amicus therapeutics Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.1.5 Amicus therapeutics Recent Development
11.2 Takeda
11.2.1 Takeda Company Detail
11.2.2 Takeda Business Overview
11.2.3 Takeda Fabry Disease Therapeutic Introduction
11.2.4 Takeda Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.2.5 Takeda Recent Development
11.3 Genzyme-Sanofi
11.3.1 Genzyme-Sanofi Company Detail
11.3.2 Genzyme-Sanofi Business Overview
11.3.3 Genzyme-Sanofi Fabry Disease Therapeutic Introduction
11.3.4 Genzyme-Sanofi Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.3.5 Genzyme-Sanofi Recent Development
11.4 Protalix
11.4.1 Protalix Company Detail
11.4.2 Protalix Business Overview
11.4.3 Protalix Fabry Disease Therapeutic Introduction
11.4.4 Protalix Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.4.5 Protalix Recent Development
11.5 Sanofi-Aventis LLC
11.5.1 Sanofi-Aventis LLC Company Detail
11.5.2 Sanofi-Aventis LLC Business Overview
11.5.3 Sanofi-Aventis LLC Fabry Disease Therapeutic Introduction
11.5.4 Sanofi-Aventis LLC Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.5.5 Sanofi-Aventis LLC Recent Development
11.6 Novartis Pharmaceuticals
11.6.1 Novartis Pharmaceuticals Company Detail
11.6.2 Novartis Pharmaceuticals Business Overview
11.6.3 Novartis Pharmaceuticals Fabry Disease Therapeutic Introduction
11.6.4 Novartis Pharmaceuticals Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.6.5 Novartis Pharmaceuticals Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Fabry Disease Therapeutic Introduction
11.7.4 Pfizer Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 Bristol-Myers Squibb Company
11.8.1 Bristol-Myers Squibb Company Company Detail
11.8.2 Bristol-Myers Squibb Company Business Overview
11.8.3 Bristol-Myers Squibb Company Fabry Disease Therapeutic Introduction
11.8.4 Bristol-Myers Squibb Company Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.8.5 Bristol-Myers Squibb Company Recent Development
11.9 GlaxoSmithKline plc
11.9.1 GlaxoSmithKline plc Company Detail
11.9.2 GlaxoSmithKline plc Business Overview
11.9.3 GlaxoSmithKline plc Fabry Disease Therapeutic Introduction
11.9.4 GlaxoSmithKline plc Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.9.5 GlaxoSmithKline plc Recent Development
11.10 Amgen Inc.
11.10.1 Amgen Inc. Company Detail
11.10.2 Amgen Inc. Business Overview
11.10.3 Amgen Inc. Fabry Disease Therapeutic Introduction
11.10.4 Amgen Inc. Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.10.5 Amgen Inc. Recent Development
11.11 Teva pharmaceutical Industries Ltd.
11.11.1 Teva pharmaceutical Industries Ltd. Company Detail
11.11.2 Teva pharmaceutical Industries Ltd. Business Overview
11.11.3 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Introduction
11.11.4 Teva pharmaceutical Industries Ltd. Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.11.5 Teva pharmaceutical Industries Ltd. Recent Development
11.12 Merc & Co.
11.12.1 Merc & Co. Company Detail
11.12.2 Merc & Co. Business Overview
11.12.3 Merc & Co. Fabry Disease Therapeutic Introduction
11.12.4 Merc & Co. Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.12.5 Merc & Co. Recent Development
11.13 AbbVie Inc.
11.13.1 AbbVie Inc. Company Detail
11.13.2 AbbVie Inc. Business Overview
11.13.3 AbbVie Inc. Fabry Disease Therapeutic Introduction
11.13.4 AbbVie Inc. Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.13.5 AbbVie Inc. Recent Development
11.14 Takeda Pharmaceutical Co. Ltd.
11.14.1 Takeda Pharmaceutical Co. Ltd. Company Detail
11.14.2 Takeda Pharmaceutical Co. Ltd. Business Overview
11.14.3 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Introduction
11.14.4 Takeda Pharmaceutical Co. Ltd. Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.14.5 Takeda Pharmaceutical Co. Ltd. Recent Development
11.15 Green Cross Corp.
11.15.1 Green Cross Corp. Company Detail
11.15.2 Green Cross Corp. Business Overview
11.15.3 Green Cross Corp. Fabry Disease Therapeutic Introduction
11.15.4 Green Cross Corp. Revenue in Fabry Disease Therapeutic Business (2019-2024)
11.15.5 Green Cross Corp. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
